Autonomix Medical, Inc. (AMIX) Stock Price & Analysis
Autonomix Medical, Inc. (AMIX) fell 16.57% to USD 2.92 as of July 25, 2026 at 09:56 UTC, according to Nexqual real-time market data.
AMIX last closed at USD 3.5; the session ranged USD 2.9–3.73 on volume of 7,987,453 shares. Market capitalization is $1.59M, with a 52-week range of USD 2.9–32.55 (NCM). Source: Nexqual, July 25, 2026 at 09:56 UTC.
Key Statistics (as of July 25, 2026 at 09:56 UTC)
| Price | USD 2.92 |
|---|---|
| Change | ▼ 16.57% (down) |
| Previous Close | USD 3.5 |
| Open | USD 3.45 |
| Day Range | USD 2.9 – 3.73 |
| 52-Week Range | USD 2.9 – 32.55 |
| Volume | 7,987,453 shares |
| Market Cap | $1.59M |
| Exchange | NCM |
Technical Analysis (AMIX)
Nexqual's technical model rates AMIX "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:56 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 16.69 (oversold) |
| vs SMA50 | Below (USD 6.91) |
| MACD | -1.01 (negative) |
Analyst Ratings (AMIX)
Wall Street analysts rate AMIX "None" based on 2 analysts, with a mean price target of USD 58.8 (range USD 42–75.6), per Nexqual as of July 25, 2026 at 09:56 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 58.8 |
| High Target | USD 75.6 |
| Low Target | USD 42 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (AMIX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -7.56 vs est -9.66 ▲ beat |
| 2025-09-30 | USD -28.98 vs est -31.5 ▲ beat |
| 2025-06-30 | USD -22.47 vs est -20.58 ▼ miss |
Source: Nexqual, July 25, 2026 at 09:56 UTC.
Financials & Fundamentals (AMIX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -238.89% |
| Current Ratio | 4.45 |
| Total Cash | $7.00M |
| Total Debt | $0 |
| Free Cash Flow | $-6.49M |
Source: Nexqual, July 25, 2026 at 09:56 UTC.
Financial Health Score (AMIX)
Nexqual rates Autonomix Medical, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:56 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $7M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M |
| Efficiency | Critical — ROE -239%, ROA -122.3% |
Ownership (AMIX)
| Insider Ownership | +4.11% |
|---|---|
| Institutional Ownership | +4.22% |
| Shares Outstanding | 543,000 |
| Float | 526,438 |
| Short % of Float | +11.73% |
Source: Nexqual, July 25, 2026 at 09:56 UTC.
Leadership (AMIX)
Autonomix Medical, Inc. is led by Bradley Hauser (age 48), CEO & President, per Nexqual as of July 25, 2026 at 09:56 UTC.
| CEO & President | Bradley Hauser (age 48) |
|---|---|
| Executive Vice Chairman | Lori H. Bisson (age 53) |
| Co-Founder & Independent Director | David A. Robins (age 55) |
| Chief Financial Officer | Trent N. Smith (age 56) |
| Executive Chairman | Walter V. Klemp (age 65) |
Major Backers & Investors (AMIX)
Notable institutional backers of Autonomix Medical, Inc. include Fidelity, Mariner, LLC, UBS Group AG, according to Nexqual as of July 25, 2026 at 09:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.52% |
| Mariner, LLC | 0.46% |
| UBS Group AG | 0.29% |
| LPL Financial LLC | 0.28% |
| Bank of Montreal /CAN/ | 0.22% |
| Ikarian Capital, LLC | 0.16% |
| Virtu Financial LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.54% |
Source: Nexqual, July 25, 2026 at 09:56 UTC.
From Autonomix Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-05-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system.
- The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system.
- It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VSEE | VSee Health, Inc. | USD 0.08 | ▼ 1.25% |
| AZTR | Azitra Inc | USD 0.13 | ▼ 3.08% |
| MIRA | MIRA Pharmaceuticals, Inc. | USD 0.88 | ▼ 4.98% |
| TRNR | Interactive Strength Inc. | USD 3.17 | ▼ 0.94% |
| NIVF | NewGenIvf Group Limited | USD 1.1 | ▼ 13.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:56 UTC. This page is informational and not investment advice.